C07K 14/55
Il-2
C07K14/55 (Il-2) appears on 914 US grants and 1,469 published applications in this corpus.
Search patents in C07K- Granted patents
- 914
- Published applications
- 1,469
- Assignees
- 589
- Inventors
- 2,673
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1983 | 5 | 0 |
| 1984 | 2 | 0 |
| 1985 | 4 | 0 |
| 1986 | 7 | 0 |
| 1987 | 13 | 0 |
| 1988 | 14 | 0 |
| 1989 | 12 | 0 |
| 1990 | 14 | 0 |
| 1991 | 9 | 0 |
| 1992 | 12 | 0 |
| 1993 | 8 | 0 |
| 1994 | 11 | 0 |
| 1995 | 6 | 0 |
| 1996 | 8 | 0 |
| 1997 | 27 | 0 |
| 1998 | 27 | 0 |
| 1999 | 30 | 0 |
| 2000 | 15 | 0 |
| 2001 | 15 | 5 |
| 2002 | 5 | 11 |
| 2003 | 13 | 25 |
| 2004 | 6 | 25 |
| 2005 | 9 | 24 |
| 2006 | 11 | 20 |
| 2007 | 14 | 19 |
| 2008 | 10 | 16 |
| 2009 | 14 | 12 |
| 2010 | 13 | 13 |
| 2011 | 13 | 21 |
| 2012 | 9 | 11 |
| 2013 | 10 | 18 |
| 2014 | 17 | 31 |
| 2015 | 11 | 16 |
| 2016 | 17 | 25 |
| 2017 | 14 | 38 |
| 2018 | 17 | 37 |
| 2019 | 26 | 69 |
| 2020 | 38 | 87 |
| 2021 | 50 | 142 |
| 2022 | 51 | 158 |
| 2023 | 64 | 179 |
| 2024 | 92 | 203 |
| 2025 | 93 | 146 |
| 2026 | 58 | 118 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Fusion polypeptide and polypeptide dimer, and use thereof29 Sep 2026US 12,747,275 B2Nanjing Normal University
- Human interleukin-2 variant or derivative thereof1 Sep 2026US 12,723,067 B2Jiangsu Hengrui Medicine Co., Ltd.
- Monoclonal antibody-cytokine fusion protein dimer and application thereof1 Sep 2026US 12,723,080 B2Nanjing GenScript Biotech Co., Ltd.
- Treatment using cytokine encoding RNA18 Aug 2026US 12,708,643 B2BioNTech SE
- Protein heterodimer and use thereof18 Aug 2026US 12,709,638 B2Ningbo Innovative Mechanism Bioscience LLC
- Fusion proteins of il-24 and immunostimulatory cytokines, nk cells expressing il-24 or fusion proteins, and methods of use thereof8 Oct 2026US 2026/0308218 A1Virginia Commonwealth University
- Human interleukin-2 variant or derivative thereof8 Oct 2026US 2026/0308220 A1Jiangsu Hengrui Medicine Co., Ltd.
- Il-12 mutants with reduced toxicity, compositions thereof and methods of using the same1 Oct 2026US 2026/0295010 A1
- Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof1 Oct 2026US 2026/0297151 A1Medicenna Therapeutics Inc.
- Methods and compositions for treating cancer1 Oct 2026US 2026/0297152 A1
Most cited
By later US patents
- Site-specific homogeneous modification of polypeptides317US 4,904,584 AGenetics Institute, Inc. · 1990
- Human recombinant interleukin-2 muteins297US 4,518,584 ACetus Corporation · 1985
- Expression and export technology of proteins as immunofusins276US 5,541,087 AFuji ImmunoPharmaceuticals Corporation · 1996
- Preparation of an activated polymer ester for protein conjugation269US 5,281,698 ACetus Oncology Corporation · 1994
- Chimeric receptor molecules for delivery of co-stimulatory signals260US 5,686,281 ACell Genesys, Inc. · 1997